WO2013009142A3 - Sustained/release pharmaceutical composition comripising choline alfoscerate or pharmaceutically acceptable salt thereof and method for manufacturing the same - Google Patents

Sustained/release pharmaceutical composition comripising choline alfoscerate or pharmaceutically acceptable salt thereof and method for manufacturing the same Download PDF

Info

Publication number
WO2013009142A3
WO2013009142A3 PCT/KR2012/005621 KR2012005621W WO2013009142A3 WO 2013009142 A3 WO2013009142 A3 WO 2013009142A3 KR 2012005621 W KR2012005621 W KR 2012005621W WO 2013009142 A3 WO2013009142 A3 WO 2013009142A3
Authority
WO
WIPO (PCT)
Prior art keywords
sustained
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
comripising
Prior art date
Application number
PCT/KR2012/005621
Other languages
French (fr)
Other versions
WO2013009142A2 (en
Inventor
Sang-Joon Lee
Kwan-Young Chang
Jae-Soon Ahn
Jae-Min Cho
Kyoung-Un Kang
Dae-Sik NAM
Hyun-Joo Lee
Original Assignee
Bio Pharmartis Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Pharmartis Co., Ltd. filed Critical Bio Pharmartis Co., Ltd.
Priority to CN201280034979.3A priority Critical patent/CN103717223A/en
Publication of WO2013009142A2 publication Critical patent/WO2013009142A2/en
Publication of WO2013009142A3 publication Critical patent/WO2013009142A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Abstract

The present invention relates to a sustained-release formulation comprising choline alfoscerate or a pharmaceutically acceptable salt thereof, and a preparation method thereof. More particularly, the present invention relates to a sustained-release pharmaceutical composition comprising a drug compartment including choline alfoscerate or a pharmaceutically acceptable salt thereof, a coating compartment that is formed on the surface of the drug compartment, and a pharmaceutically acceptable sustained-release base material, and a preparation method thereof.
PCT/KR2012/005621 2011-07-14 2012-07-13 Sustained/release pharmaceutical composition comripising choline alfoscerate or pharmaceutically acceptable salt thereof and method for manufacturing the same WO2013009142A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201280034979.3A CN103717223A (en) 2011-07-14 2012-07-13 Sustained/release pharmaceutical composition comripising choline alfoscerate or pharmaceutically acceptable salt thereof and method for manufacturing the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0069969 2011-07-14
KR1020110069969A KR101257918B1 (en) 2011-07-14 2011-07-14 Sustained-release pharmaceutical composition comprising choline alfoscerate or pharmaceutically acceptable salt thereof and method for manufacturing the same

Publications (2)

Publication Number Publication Date
WO2013009142A2 WO2013009142A2 (en) 2013-01-17
WO2013009142A3 true WO2013009142A3 (en) 2013-04-11

Family

ID=47506749

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/005621 WO2013009142A2 (en) 2011-07-14 2012-07-13 Sustained/release pharmaceutical composition comripising choline alfoscerate or pharmaceutically acceptable salt thereof and method for manufacturing the same

Country Status (3)

Country Link
KR (1) KR101257918B1 (en)
CN (1) CN103717223A (en)
WO (1) WO2013009142A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102008490B1 (en) * 2013-01-14 2019-08-08 주식회사 바이오파마티스 Controlled release pharmaceutical composition comprising choline alfoscerate or pharmaceutically acceptable salt thereof and method for manufacturing the same
KR101631846B1 (en) 2014-07-08 2016-06-20 한국유나이티드제약 주식회사 Solid preparations containing choline alfoscerate and preparing method thereof
KR101628937B1 (en) 2014-11-06 2016-06-09 환인제약 주식회사 Pharmaceutical tablet comprising Choline Alphoscerate and method for manufacturing the same
CN105061494B (en) * 2015-08-12 2017-09-01 芜湖福民生物药业有限公司 The preparation method of Choline Glycerophosphate crystal
CN105131029B (en) * 2015-08-12 2017-09-01 芜湖福民生物药业有限公司 The preparation method of Choline Glycerophosphate crystal
KR102265977B1 (en) * 2018-07-16 2021-06-16 주식회사 코피텍 Composition for film-coating having improved damp-proof property and tablet coated with the composition
KR20200021774A (en) * 2018-08-21 2020-03-02 대화제약 주식회사 Methods of manufacturing formulations comprising sitagliptin immediate release layer, and the formulations manufactured by the methods, methods of sitagliptin immediate release layer coating, and compositions for sitagliptin immediate release layer coating
KR102149020B1 (en) * 2018-11-20 2020-08-28 주식회사 코피텍 Film-coated tablet having high damp proof property
KR102381836B1 (en) 2019-10-22 2022-04-05 한국유나이티드제약 주식회사 Minimized and Sustained Released Pharmaceutical Dosage Form Comprising Choline Alfoscerate
KR102285886B1 (en) 2019-10-22 2021-08-05 한국유나이티드제약 주식회사 Sustained-Release Minimized Oral Dosage Formulation Comprising Choline Alfoscerate
KR20210105761A (en) 2020-02-19 2021-08-27 한국프라임제약주식회사 A sustained release dosage form comprising choline alphoscerate as an active ingredient
CN115010336B (en) * 2022-06-27 2023-10-20 上海交通大学 Method for producing methane by sludge anaerobic digestion based on slow-release choline

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070118444A (en) * 2006-06-12 2007-12-17 신풍제약주식회사 Controlled release formulation containing loxoprofen or zaltoprofen and process for the preparation thereof
KR20090088564A (en) * 2008-02-15 2009-08-20 주식회사 씨티씨바이오 Pharmaceutical preparation containing choline alfoscerate
WO2011049309A2 (en) * 2009-10-09 2011-04-28 영진약품공업 주식회사 Pharmaceutical composition with both immediate and extended release characteristics
KR20110068985A (en) * 2008-07-30 2011-06-22 파나세아 바이오테크 리미티드 Modified release ramipril compositions and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7254239B2 (en) * 2001-02-09 2007-08-07 Thx Ltd. Sound system and method of sound reproduction
KR101172699B1 (en) * 2011-05-16 2012-08-09 한국프라임제약주식회사 Pharmaceutical preparation comprising choline alfoscerate, and a method for manufacturing the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070118444A (en) * 2006-06-12 2007-12-17 신풍제약주식회사 Controlled release formulation containing loxoprofen or zaltoprofen and process for the preparation thereof
KR20090088564A (en) * 2008-02-15 2009-08-20 주식회사 씨티씨바이오 Pharmaceutical preparation containing choline alfoscerate
KR20110068985A (en) * 2008-07-30 2011-06-22 파나세아 바이오테크 리미티드 Modified release ramipril compositions and uses thereof
WO2011049309A2 (en) * 2009-10-09 2011-04-28 영진약품공업 주식회사 Pharmaceutical composition with both immediate and extended release characteristics

Also Published As

Publication number Publication date
WO2013009142A2 (en) 2013-01-17
CN103717223A (en) 2014-04-09
KR20130010044A (en) 2013-01-24
KR101257918B1 (en) 2013-04-30

Similar Documents

Publication Publication Date Title
WO2013009142A3 (en) Sustained/release pharmaceutical composition comripising choline alfoscerate or pharmaceutically acceptable salt thereof and method for manufacturing the same
WO2012131463A3 (en) Controlled release pharmaceutical dosage forms
WO2015184256A3 (en) Biodegradable lipids for delivery of nucleic acids
WO2011076749A3 (en) Solid pharmaceutical dosage form of ticagrelor
WO2011086531A3 (en) New anti-malarial agents
PL2750667T3 (en) Sustained-release lipid pre-concentrate of pharmacologically active substance and pharmaceutical composition comprising the same
BRPI0910758A2 (en) thermostable solid composition, pharmaceutical composition, processes for preparing a thermostable solid composition and a pharmaceutical composition, method for improving the bioavailability of a pharmaceutically active ingredient, and
WO2013100566A8 (en) Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same
WO2011157721A3 (en) Ivabradine-containing pharmaceutical composition
WO2012001705A3 (en) Pharmaceutical compositions of (r)-lansoprazole
WO2012101653A3 (en) Modified release pharmaceutical compositions memantine
WO2013093931A3 (en) Novel prodrugs of phenolic drugs
WO2014207664A3 (en) Stable pharmaceutical composition of asenapine
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
MD4563C1 (en) Co-micronisation product comprising ulipristal acetate
WO2014016754A3 (en) Pharmaceutical compositions of proton pump inhibitor
WO2013169746A3 (en) N-ethyl-4-hydroxyl-1-methyl-5- (methyl(2,3,4,5,6-pentahydroxyhexyl) amino) -2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide
JP2015508411A5 (en)
WO2013017910A8 (en) Extended release pharmaceutical compositions containing paliperidone
EP2394644A3 (en) Trimetazidine Formulation With Different Release Profiles
MA33883B1 (en) The process of formation and crystalline form of hydrochloride 4} 3] c-hexanhydrochlopitan [c] pyrrol-2 (1h)-[yl propoxy {benzamide and the pharmaceutical formulations it contains
EP2722322B8 (en) 1,3-di-oxo-indene derivative, pharmaceutically acceptable salt or optical isomer thereof, preparation method thereof, and pharmaceutical composition containing same as an antiviral, active ingredient
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
CO6721030A2 (en) Formulation of a complex comprising lercanidipine hydrochloride and valsartan and method for preparing it
WO2012127495A3 (en) Pharmaceutical composition and process for preparation thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12811581

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12811581

Country of ref document: EP

Kind code of ref document: A2